Potential of valsartan+sacubitril therapy in hypertensive heart disease
The course of hypertension is often complicated by left ventricular hypertrophy (or hypertensive heart disease, HHD). The main “corridor” of natural HHD is development of heart failure with preserved ejection fraction (HFpEF). With HFpEF, the bioavailability of natriuretic peptides (NP) is significa...
Saved in:
Main Authors: | A. G. Ovchinnikov, A. D. Gvozdeva, A. V. Potekhina, M. V. Vitsenya, F. T. Ageev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2021-08-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4568 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Experience of sacubitril/valsartan therapy in hypertension
by: E. V. Oshchepkova
Published: (2023-09-01) -
Natriuretic peptides: new challenges — new solutions
by: O. M. Drapkina, et al.
Published: (2021-11-01) -
EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018-05-01) -
EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
by: Zh. D. Kobalava, et al.
Published: (2017-07-01) -
Predictors of unfavorable progression and prognosis in patients with heart failure with preserved left ventricular ejection fraction
by: M. S. Sobolevskaya, et al.
Published: (2024-12-01)